Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process development—enhancing its capabilities in monoclonal antibody (mAb) development and manufacturing by enabling highly efficient, scalable perfusion-based bioprocessing from early-stage development to large-scale manufacturing. The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture system. By incorporating Breez int...